Loading
A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Medicenna Therapeutics, Inc., now recruiting.
A Beta-only IL-2 ImmunoTherapY Study is a phase 1/2 interventional study registered as NCT05086692 by Medicenna Therapeutics, Inc., with 115 participants planned, started 2021-08-27 and due to reach its primary completion in 2026-06-30. Interventions recorded: MDNA11, Pembrolizumab (KEYTRUDA®). Conditions listed: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.